Background: Mantle cell lymphoma (MCL) is aggressive, and relapsed/refractory disease has poor outcomes. Patients and methods: Thirty-nine patients (men = 34, women = 5) at 64 (41-82) years of age with relapsed/refractory MCL, ineligible for high-dose chemotherapy and had received 2 (1-5) prior regimens, were treated with a continuous oral regimen, comprising oral arsenic trioxide (oral-As 2 O 3 ), chlorambucil and ascorbic acid.
introduction
Mantle cell lymphoma (MCL) constitutes 5%-7% of all nonHodgkin lymphomas [1] . Patients commonly have advanced disease with generalized nodal and marrow involvement. MCL is characterized by CD5+, CD20+ and cyclin D1+ neoplastic cells [2] , with translocation t(11;14)(q13;q32) [1] .
Aggressive treatment with rituximab plus hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate and cytarabine) induces high remission rates exceeding 80% [3] . Conventional treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is less intensive, with lower response rates. Recently, rituximab plus bendamustine has been shown to result in outcome superior to R-CHOP [4] . However, responses are short for a median of 1.5-3 years [2] . Intensive chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) improves outcome, but is only suitable for younger patients [3] .
In relapsed/refractory MCL, optimal treatment remains undefined. As many patients are elderly, therapeutic aim is mostly palliative. Novel agents against cellular pathways activated in MCL, including bortezomib (targeting NFκB) [5, 6] , temsirolimus (targeting m-TOR) [7] , lenalidamide (targeting angiogenesis, immunomodulation, microenvironment/stromal interactions) [8] [9] [10] and Bruton's tyrosine kinase inhibitor (targeting B-cell receptor) [11] , have all shown activities.
Oral arsenic trioxide (As 2 O 3 ) was initially developed for relapsed acute promyelocytic leukemia (APL) [12] . As 2 O 3 induces apoptosis, targets cellular signaling pathways and down-regulates BCL-2 [13] . Evidence in vitro also suggested that As 2 O 3 might be effective in lymphoma [14] .
In this study, we investigated the use of an oral-As 2 O 3 -based regimen for the treatment of relapsed/refractory MCL.
patients and methods patients
As part of a pilot study examining oral-As 2 O 3 in the salvage treatment of hematologic malignancies [15] , patients with refractory/relapsed lymphomas were recruited. In the initial cohort where oral-As 2 O 3 was used as a single agent or combined with chemotherapy, none of the lymphomas (diffuse large B-cell lymphoma, n = 6; follicular lymphoma, n = 6; small lymphocytic lymphoma, n = 4; lymphoplasmacytic lymphoma, n = 1; marginal zone B-cell lymphoma, n = 3) other than MCL responded. A subsequent single-center study therefore focused only on MCL patients. All patients gave informed consent, and the use of oral-As 2 O 3 was approved by the institution review board.
study design
Inclusion criteria included age >18 years, Eastern Cooperative Oncology Group (ECOG) performance score of ≤2, previous treatment with ≥1 standard regimens, measurable diseases, and ineligibility for HSCT. Exclusion criteria included inadequate liver function (bilirubin ≥50 μmol/l and/or alanine aminotransferase >3 times upper limit of normal) and renal function (serum creatinine >150 μmol/l). Histopathologic and immunophenotypic diagnoses were according to standard criteria. Positivity for cyclin D1 and/or t(11;14)(q13;q32) was confirmed with immunohistochemistry and fluorescence in situ hybridization.
diagnostic evaluations
All recruited patients had standard staging investigations. Computed tomography (CT) was used for imaging. Positron emission tomography-CT (PET-CT) was also allowed, with standard response criteria adopted. treatment Doses of oral-As 2 O 3 and ascorbic acid were similar to those shown to be safe and efficacious in APL [15] . Chlorambucil dosing was also standard. Induction treatment lasted 6 weeks, comprising oral-As 2 O 3 (10 mg/day, reduced to 5 mg/day in 4 weeks), oral chlorambucil (starting at 4 mg/day, increasing to 8 mg/day if leukocyte count allowed) and oral ascorbic acid (1000 mg/day). After 6 weeks, patients who showed disease progression were taken off treatment. Otherwise, patients were then treated with oral-As 2 O 3 (3 mg/day), chlorambucil (2 mg/day) and ascorbic acid (300 mg/day) continuously, until documented disease progression.
response assessment
Patients were evaluated in the outpatient department every 2-4 weeks. Responses were assessed at 3 months, clinically and radiologically (CT or PET-CT). Complete response (CR), partial response (PR), stable disease (SD) and disease progression were defined by standard criteria. For patients achieving CR, radiologic assessment was carried out annually. For patients with PR or SD, radiologic assessments were carried out every 3-6 months until CR or disease progression, according to reimbursement limits.
adverse effects
Adverse effects were graded according to standard WHO criteria. Electrocardiogram (ECG) was carried out during each follow-up, and corrected QT interval (QTc) determined. Treatment was suspended when neutrophil count was <1 × 10 9 /l, alanine aminotransferase was >3 times the upper reference range or if other toxicities of ≥ grade III occurred; and resumed without dose reduction on recovery.
data analysis
The recruitment period was 1 January 2003 to 1 October 2011. Data were censored on 31 December 2012. Overall survival (OS) was defined as time from recruitment to death or last follow-up. Progression-free survival (PFS) was defined as time from oral-As 2 O 3 treatment to disease relapse or progression, initiation of next treatment, death or last follow-up. Categorical data were analyzed with the χ 2 test. Continuous variables were analyzed using the Mann-Whitney U-test. 
adverse effects
Treatment was remarkably well tolerated, with grade I/II hematologic toxicities (anemia: 13%; neutropenia: 39%; thrombocytopenia: 3%), and grade I/II hepatotoxicity (8%). There were no grade III/IV toxicities. No QTc prolongation was observed. No patients had treatment discontinuation due to toxicity.
treatment outcome
The median follow-up was 21 (1-118) months. The best response was CR in 11 patients (28%), after a median of 6 (4-12) months, and PR in 8 patients (21%), after a median of 5.5 (2-12) months ( Figure 1A and B) ; so that the overall response rate (ORR) was 49% (examples of CR were shown in Figure 2 ). Disease progression occurred subsequently in 8 (44%) of these patients, after a median of 72 months of response (95% confidence interval: 30.6-113.4). Response was maintained in 11 patients (CR, n = 8; PR, n = 3), after a median of 24 (2-108) months. SD was achieved in 13 patients for a median of 12 (4-62) months. Subsequent disease progression occurred in 12 of these patients, after a median of 12 months (95% confidence interval: 7.4-16.6) (supplementary File S3, available at Annals of Oncology online). Univariate analysis showed that response (CR + PR) was significantly affected by LDH (P = 0.04), ECOG performance score (P = 0.02), IPI (P = 0.02), MIPI (P = 0.02), number of prior regimens (P = 0.05) and stage (P = 0.03) (supplementary File S4, available at Annals of Oncology online).
Multivariate analysis showed that LDH (P = 0.04) and MIPI (P = 0.04) significant impacted on the achievement of response.
progression-free survival
The median PFS was 16 months (95% confidence interval: 3.0-29.0) ( Figure 3A) . The 2-and 5-year PFS were 41% and 29%. Twenty-one patients had died, 20 due to refractory lymphoma and 1 due to community-acquired pneumonia. Univariate analysis showed that PFS was negatively impacted by female gender (P < 0.001), ECOG performance score of 2 (P = 0.001), stage III/ IV disease (P = 0.02) and non-response to As 2 O 3 (P < 0.001) ( Figure 3B-D) . Multivariate analysis showed that female gender (P = 0.002), ECOG performance score of 2 (P = 0.009) and nonresponse to As 2 O 3 (P < 0.001) were independent prognostic indicators. The median OS was 38 months (95% confidence interval: 15.8-56.2) ( Figure 3E ). The 2-and 5-year OS were 56% and 43%. Univariate analysis showed that OS was negatively impacted by female gender (P < 0.001), ECOG performance score of 2 (P = 0.02), stage III/IV disease (P = 0.04), non-response to As 2 O 3 (P < 0.001) and disease progression after an initial CR, PR or SD (P = 0.002) ( Figure 3F-I ). Multivariate analysis showed that female gender (P < 0.001), ECOG performance score of 2 (P = 0.03), non-response to As 2 O 3 (P < 0.001) and disease progression after an initial CR, PR or SD (P = 0.05) were independent prognostic indicators.
discussion
The current regimen was purposefully designed to be entirely oral and administered at home. Induction comprised oralAs 2 O 3 (10 mg/day) and ascorbic acid (1000 mg/day) for 6 weeks, which were doses typically used in APL [15] . The maintenance phase also employed drug doses comparable with APL [15] ). Ascorbic acid in combination with oral-As 2 O 3 is safe in APL [15] , and has been tested in lymphoid malignancies [16] . Ascorbic acid might work by depleting intracellular glutathione, thereby enhancing As 2 O 3 -mediated apoptosis [15] . Chlorambucil had been included in a few regimens for MCL. In previously untreated newly diagnosed patients, the MCP (mitoxantrone, chlorambucil, prednisone) regimen gave an ORR of 73%, and a CR rate of 20% [17] ; whereas the R-VAD+C (rituximab, vincristine, adriamycin, dexamethasone, chlorambucil) regimen gave an ORR of 73%, and a CR rate of 46% [18] .
In another small study of 20 patients with newly diagnosed indolent low-risk MCL, rituximab+chlorambucil induced an ORR of 95%, and a CR rate of 90% [19] . Hence, chlorambucil is The results were impressive, given that over 90% of our cases had stage III/IV lymphoma with progressive disease, ∼70% of patients had marrow infiltration and hence considerable disease burden, and over 70% of patients had received ≥2 regimens. These results compare very favorably with those reported for other novel agents in relapsed/refractory MCL (supplementary File S5, available at Annals of Oncology online) [5] [6] [7] [8] [9] [10] [11] . Our regimen showed a CR of 28% that was among the best in this group of drugs, which varied from 0% to 21%. Our ORR of 49% was also comparable or superior to most of them (6-53%), except ibrutinib with an ORR of ∼70%. Importantly, our regimen was associated with minimal adverse effects. None of our patients showed grade 3/4 toxicities, which occurred in 11%-59% of patients receiving other novel agents. QTc prolongation was not found, consistent with the observed cardiac safety of long-term oral-As 2 O 3 [20] . Our survivals were also very impressive, with PFS and OS comparable with ibrutinib [11] , and superior to all other novel agents. Finally, response was still maintained in 11 (26%) of 39 patients for a median of 2 years.
More intensive treatment has been given to relapsed/refractory MCL. A combination of rituximab, bendamustine and medium-dose cytarabine (2.4 g/m 2 ) was recently reported to give an ORR of 80% (CR: 70%) in 20 relapsed/refractory MCL patients, and a 2-year PFS of 70% [21] . However, these were patients especially recruited for having received just one previous regimen. Even then, severe toxicities occurred in 68% of patients. In a study of 202 patients with relapsed/refractory MCL, allogeneic HSCT (non-myeloablative and myeloablative) in chemotherapy-unresponsive MCL patients gave poor results, with a 100-day non-relapse mortality of 26%-33%, and a 1-year PFS of merely 31%-38% [22] . These results showed that more intensive treatment for relapsed/refractory MCL gave only unsatisfactory results, except for highly selected patients.
It is uncertain whether chlorambucil at low doses and on its own might be efficacious in relapsed/refractory MCL. As 2 O 3 is likely to be an important component. First, As 2 O 3 enhances the ubiquitination and hence degradation of cyclin D1 in MCL cell lines and primary patient samples [23] . Secondly, an anecdotal case of concomitant MCL and APL had been reported to respond to As 2 O 3 , which induced as a single agent a complete response of both diseases [24] . Finally, intravenous-As 2 O 3 combined with ascorbic acid resulted in CR-unconfirmed in 1 of 18 cases of refractory lymphomas, which was a patient with MCL [16] .
Because of the long recruitment, prior chemotherapies were heterogeneous, and some patients had not received rituximab. Furthermore, interpretation of the prognostic significance of gender and performance score is somewhat confounded by the relatively small sample size, although these prognostic factors could provide useful leads in the design of future studies.
In conclusion, we have provided the first clinical evidence that an entirely oral regimen with oral-As 2 O 3 , chlorambucil and ascorbic acid was active with minimal toxicity in relapsed/refractory MCL. Future investigations should be directed at defining if As 2 O 3 should be given at low doses continuously, or as blocks of higher doses. Furthermore, regimens combining As 2 O 3 with other novel agents active in MCL should be explored.
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